증권사 리포트&코멘트
Fresenius’ Partner, SamChunDang Pharm Received FDA Acceptance for Review of its Proposed …
fresenius-kabi
Fresenius’ Partner, SamChunDang Pharm Received FDA Acceptance for Review of its Proposed Aflibercept Biosimilar Dossier
Fresenius announced today that the FDA has accepted for review Fresenius Kabi’s partner SamChunDang Pharm’s (SCD) application for a proposed aflibercept biosimilar.
외부 자료를 정리한 참고자료이며 투자 권유가 아닙니다. 기사·리포트의 저작권은 원저작자에게 있습니다. · 게시중단 요청